Treatment Selection in Rheumatoid Arthritis

In this module, Stanley B. Cohen, MD, describes the general principles recommended in managing rheumatoid arthritis, including:
  • Treating to target
  • Monitoring disease activity
  • Treatment selection
Stanley B. Cohen, MD
Physicians: maximum of 0.5 AMA PRA Category 1 Credits
Released: February 3, 2017 Expiration: February 2, 2018

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply guidelines for treatment targets and disease monitoring to optimize the care of patients with rheumatoid arthritis
  • Integrate clinical guidelines and clinical trial findings into treatment decisions at the point of care to improve patient outcomes for patients with rheumatoid arthritis
  • Discuss the future directions of novel agents in development and approved agents in clinical trials for the management of rheumatoid arthritis

Acknowledgements

Jointly provided by Boston University School of Medicine and Clinical Care Options, LLC

Boston University School of Medicine
Continuing Medical Education
72 East Concord Street, A402
Boston, Massachusetts 02118

(617) 638-4605
(617) 638-4905 (Fax)
http://www.bu.edu/cme

Supported by educational grants from
Genentech
Lilly USA, LLC

Information on this Educational Activity

Disclosure of Conflicts of Interest

Boston University School of Medicine asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all relationships with commercial interests. This information is disclosed to CME activity participants. Boston University School of Medicine has procedures to resolve any apparent conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.

Faculty

Stanley B. Cohen, MD

Clinical Professor
Department of Internal Medicine
University of Texas Southwestern Medical School
Co-Director
Division of Rheumatology
Presbyterian Hospital
Co-Medical Director
Metroplex Clinical Research Center
Dallas, Texas

Stanley B. Cohen, MD, has disclosed that he has received funds for research support from Amgen, Biogen, Bristol-Myers Squibb, Centocor, Genentech, Johnson & Johnson, Pfizer, Merck, and Roche.

Staff

Alyce Kuklinski, NP, RN

General Manager, Virology & Other Therapeutic Specialties

Alyce Kuklinski, NP, RN, has nothing to disclose with regard to commercial interests.

Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, ELS, has nothing to disclose with regard to commercial interests.

Heather Stieglitz, PhD

Editorial Contributor

Heather Stieglitz, PhD, has nothing to disclose with regard to commercial interests.

Disclaimer
THESE MATERIALS AND ALL OTHER MATERIALS PROVIDED IN CONJUNCTION WITH CONTINUING MEDICAL EDUCATION ACTIVITIES ARE INTENDED SOLELY FOR PURPOSES OF SUPPLEMENTING CONTINUING MEDICAL EDUCATION PROGRAMS FOR QUALIFIED HEALTH CARE PROFESSIONALS. ANYONE USING THE MATERIALS ASSUMES FULL RESPONSIBILITY AND ALL RISK FOR THEIR APPROPRIATE USE. TRUSTEES OF BOSTON UNIVERSITY MAKES NO WARRANTIES OR REPRESENTATIONS WHATSOEVER REGARDING THE ACCURACY, COMPLETENESS, CURRENTNESS, NONINFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF THE MATERIALS. IN NO EVENT WILL TRUSTEES OF BOSTON UNIVERSITY BE LIABLE TO ANYONE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE MATERIALS. IN NO EVENT SHOULD THE INFORMATION IN THE MATERIALS BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE.

Target Audience

This activity is intended for physicians and other healthcare professionals involved in the medical management of patients with rheumatologic conditions.

Goal

The goal of this activity is to improve the knowledge and competence of physicians and other healthcare providers for the prevention, diagnosis, and treatment of patients with rheumatologic conditions.

Physician Continuing Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Boston University School of Medicine and Clinical Care Options, LLC. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Boston University School of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from February 03, 2017, through February 02, 2018:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Expert commentary on real-world and trial data on treating RA after failing biologic and targeted small-molecule DMARDs, from EULAR 2020 by CCO

Eric M. Ruderman, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: August 27, 2020 Expired: August 26, 2021

Expert commentary on key studies in RA comorbidities from EULAR 2020 as reported by CCO

Paul Emery, MA, MD, FRCP Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: August 24, 2020 Expired: August 23, 2021

EULAR 2020 on SELECT-CHOICE: upadacitinib vs abatacept for active rheumatoid arthritis with prior inadequate response or intolerance to bDMARDs as reported by CCO

Released: August 17, 2020

New from EULAR 2020: risk of venous thromboembolism (DVT or PE) varies by DAS28 in patients with rheumatoid arthritis as reported by Clinical Care Options (CCO)

Released: August 13, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?